Palivizumab leads to lower number of children reporting any SAE compared with placebo (high certainty).
Palivizumab showed no clear difference in hospitalisation for RSV infection compared with motavizumab (moderate certainty).
Palivizumab showed no clear difference in all‐cause mortality compared with motavizumab (moderate certainty).
The intervention showed no clear difference in mortality Mortality at latest (low certainty).
Interleukin‐2 RA showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with no induction (low certainty).
Interleukin‐2 RA showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with no induction (low certainty).
Interleukin‐2 RA showed no clear difference in cancer Number of participants diagnosed with cancer compared with no induction (low certainty).
The intervention showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy (low certainty).
The intervention showed no clear difference in infection Number of participants diagnosed with infection (low certainty).
The intervention showed no clear difference in cytomegalovirus infection Number of patients diagnosed with CMV… (low certainty).
The intervention showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… (low certainty).
The intervention showed no clear difference in cancer Number of participants diagnosed with cancer (low certainty).
Interleukin‐2 RA showed no clear difference in mortality Mortality at latest compared with no induction (low certainty).
Interleukin‐2 RA showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with no induction (low certainty).
Interleukin‐2 RA showed no clear difference in infection Number of participants diagnosed with infection compared with no induction (low certainty).